Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Double-Blind Study of BAN2401 in Early Alzheimer's Disease
2018-004739-58Phase 3Unknown
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing BAN2401 with Placebo (2 arms). Primary endpoint: Primary endpoint (core phase). Status: unknown.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2018-004739-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004739-58.